Filing Flows › Supernus Pharmaceuticals (SUPN) › Guidance history
Supernus Pharmaceuticals (SUPN) guidance history: what it guided and what it reported
Supernus Pharmaceuticals gave guidance in 3 earnings releases on file since Apr 30, 2026. Its releases raised guidance twice and lowered it 0 times.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $1.2B–$1.3B (Apr 30, 2026) → raised $1.3B–$1.4B (Aug 3, 2026) → reaffirmed $1.3B–$1.4B (Oct 29, 2026) | — | to be reported | — |
The latest quarter
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.
Questions
Does Supernus Pharmaceuticals beat its guidance?
Supernus Pharmaceuticals gave guidance in 3 earnings releases on file since Apr 30, 2026. Its releases raised guidance twice and lowered it 0 times.
How often does Supernus Pharmaceuticals raise guidance?
Its earnings releases raised guidance twice and lowered it 0 times since Apr 30, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.